Centrus Energy Corp vs Koninklijke Philips NV — how do they compare? Centrus Energy Corp trades at $186.95 (market cap $3.77B), while Koninklijke Philips NV trades at $26.84 (market cap $26.58B). The key difference: Koninklijke Philips NV is far larger — about 7.1× Centrus Energy Corp's market cap, and Koninklijke Philips NV pays a 3.75% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals.
| LEU | PHG | |
|---|---|---|
Market Cap | $3.77B | $26.58B |
Sector | Energy | Health |
52-Week High | $436.00 | $32.91 |
52-Week Low | $146.61 | $25.02 |
Enterprise Value | $3.08B | $33.13B |
Dividend Yield | — | 3.75% |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $186.93, down 1.27% on the day, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results, beating earnings estimates but showing margin compression. LEU maintains a strong $4.5 billion backlog and secured significant DOE funding, positioning it as a key player in the domestic nuclear fuel supply chain. Valuation metrics appear elevated with a P/E of 68.23 and P/S of 8.89, reflecting growth expectations in the nuclear energy sector.
The outlook remains positive given government support for nuclear energy and Centrus's strategic position in HALEU production. However, investors face risks from execution challenges, cost pressures, and the capital-intensive nature of enrichment facility expansion. Analyst consensus leans bullish with a $228.50 price target, though the stock's premium valuation requires careful monitoring of operational milestones and margin trends.
PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.
The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.
Trailing returns across standard periods
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →